Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1746 participants.

Also called NCT01586910

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 1,746 participants (enrolled count) (from the registry)
Sponsor
  • Medtronic Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01586910
Other papers using this trial's data
  • Clinical outcomes of TAVI or SAVR in men and women with aortic stenosis at intermediate operative risk: a post hoc analysis of the randomised SURTAVI trial EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2020-11-20 DOI, PubMed 32715995
  • Comparison of Outcomes After Transcatheter vs Surgical Aortic Valve Replacement Among Patients at Intermediate Operative Risk With a History of Coronary Artery Bypass Graft Surgery: A Post Hoc Analysis of the SURTAVI Randomized Clinical Trial JAMA cardiology, 2019-08-01 DOI, PubMed 31215985, PMC6584891 Not in the PMC Open Access subset.
  • Neurological Complications After Transcatheter Versus Surgical Aortic Valve Replacement in Intermediate-Risk Patients Journal of the American College of Cardiology, 2018-10-30 DOI, PubMed 30360820
  • Quality of Life 5 Years Following Transfemoral TAVR or SAVR in Intermediate Risk Patients JACC. Cardiovascular interventions, 2024-04-22 DOI, PubMed 38658126
  • The Impact of Transfusions on Mortality After Transcatheter or Surgical Aortic Valve Replacement The Annals of thoracic surgery, 2021-09 DOI, PubMed 33217396

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Denmark, Germany, Netherlands, Spain, Sweden, Switzerland, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT01586910. Randomized; no masking; primary purpose treatment. Start 2012-04 (actual); primary completion 2018-07 (actual). Results posted on 2019-09-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement (SURTAVI).
Acronym
SURTAVI
Condition
Severe Aortic Stenosis
Intervention (Device)
Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Intervention (Procedure)
Surgical Aortic Valve Replacement (SAVR)
Intervention (Device)
Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI)
Lead sponsor
Medtronic Cardiovascular (class: industry)

Record details

Record id
cardio:ct-nct01586910
Content hash
3e2d29f411d9caf9c0e940f324b9ff09727707b886088222ce88bcd096cac852